
About Amerise Biosciences Limited
Data last updated:
Amerise Biosciences Limited is a public limited company based in Ahmedabad, Gujarat, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 27 August 1984 and has been in existence for over 42 years.
The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN L29199GJ1984PLC007195. It is a listed company as per MCA records. Its shares are listed on BSE: 531681.
The company has an authorised share capital of ₹7.5 Cr and a paid-up capital of ₹6.61 Cr. It was formerly known as Amradeep Industries Limited. It is led by directors including Albert Hines (Whole-Time Director) and Manisha Patel Maneklal.
Its last annual general meeting (AGM) was held on 23 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at 24 Laxmi Chambers Navjeevan Press Road Opp. Old Gujarat High Court, Ahmedabad, Gujarat, India – 380014.
As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹26 Lakh, a growth of 36.8% compared to the previous year. For the same year it recorded a net profit of ₹3 Lakh (net margin 11.5%) and EBITDA of ₹3 Lakh (EBITDA margin 11.5%). The net worth stands at ₹5.4 Cr (up 0.4% YoY). Total assets are valued at ₹5.4 Cr (up 0.4% YoY).
As per MCA filings, the company has open charges of ₹38.39 Lakh on record. The company has 28 deals on record (28 market trades); the latest was in July 2026.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website amradeepindustries.in.
Company details
CIN history
Amerise Biosciences has one previous CIN (Corporate Identification Number): U29199GJ1984PLC007195. The current CIN is L29199GJ1984PLC007195, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L29199GJ1984PLC007195 | Current |
| U29199GJ1984PLC007195 | Previous |
Contact details
Amerise Biosciences Limited's registered office is in Ahmedabad, Gujarat. Its website is amradeepindustries.in. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered Address24 Laxmi Chambers Navjeevan Press Road Opp. Old Gujarat High Court, Ahmedabad, Gujarat, India – 380014
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Amerise Biosciences Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Financials of Amerise Biosciences Limited
FY 2025-26 filings availableAmerise Biosciences Limited reported revenue of ₹26 Lakh (up 36.8% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 0.26 | 0.19 | 0.04 | 0.01 | 9.58 | 0.00 | 0.00 |
| Revenue growth | +36.8% | +375.0% | +300.0% | -99.9% | - | - | - |
| EBITDA | 0.03 | 0.01 | (0.14) | (0.12) | 0.56 | (0.17) | (0.15) |
| EBITDA margin | +11.5% | +5.3% | -350.0% | -1200.0% | +5.9% | - | - |
| Profit before tax | 0.03 | 0.01 | (0.14) | (0.12) | 0.56 | (0.34) | (0.15) |
| Net profit | 0.03 | 0.01 | (0.14) | (0.12) | 0.56 | (0.34) | (0.15) |
| Net profit margin | +11.5% | +5.3% | -350.0% | -1200.0% | +5.9% | - | - |
| EPS (₹) | 0.00 | 0.00 | (0.02) | (0.02) | 0.08 | (0.05) | (0.02) |
| Balance sheet | |||||||
| Total assets | 5.40 | 5.38 | 5.37 | 5.61 | 5.72 | 5.09 | 5.43 |
| Net worth | 5.40 | 5.38 | 5.38 | 5.52 | 5.64 | 5.09 | 5.43 |
| Total debt | 0.00 | 0.00 | 0.00 | 0.09 | 0.08 | 0.00 | 0.00 |
| Cash & bank | 0.59 | 0.02 | 0.02 | 0.01 | 0.01 | 0.02 | 0.03 |
| Net working capital | (1.42) | (3.06) | 0.00 | (0.03) | (0.04) | (0.52) | (0.57) |
| Cash flow | |||||||
| Cash from operations | (1.06) | 3.07 | (0.17) | (0.13) | 0.06 | (0.39) | 4.89 |
| Cash from investing | 1.63 | (3.07) | 0.27 | 0.13 | (0.15) | 0.39 | (4.89) |
| Cash from financing | 0.00 | 0.00 | (0.09) | 0.01 | 0.08 | 0.00 | 0.00 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.08 | 0.04 | 0.07 | 0.06 | 0.19 | 0.00 | 0.00 |
| Revenue growth (YoY) | -100.0% | -57.9% | - | - | - | - | - | - |
| Other income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total expenses | 0.08 | 0.02 | 0.04 | 0.11 | 0.07 | 0.08 | 0.02 | 0.03 |
| EBITDA | (0.08) | 0.06 | 0.00 | (0.04) | (0.01) | 0.11 | (0.02) | (0.03) |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | (0.08) | 0.06 | 0.00 | (0.04) | (0.01) | 0.11 | (0.02) | (0.03) |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Financial Statements
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.08 | 0.04 | 0.07 | 0.06 | 0.19 | 0.00 | 0.00 |
| Revenue growth (YoY) | -100.0% | -57.9% | - | - | - | - | - | - |
| Other income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total expenses | 0.08 | 0.02 | 0.04 | 0.11 | 0.07 | 0.08 | 0.02 | 0.03 |
| EBITDA | (0.08) | 0.06 | 0.00 | (0.04) | (0.01) | 0.11 | (0.02) | (0.03) |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | (0.08) | 0.06 | 0.00 | (0.04) | (0.01) | 0.11 | (0.02) | (0.03) |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.26 | 0.19 | 0.04 | 0.01 | 9.58 | 0.00 | 0.00 |
| Revenue growth | +36.8% | +375.0% | +300.0% | -99.9% | - | - | - |
| Other income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.17) | 0.00 |
| Total expenses | 0.23 | 0.18 | 0.18 | 0.13 | 9.02 | 0.17 | 0.15 |
| Employee cost | 0.00 | 0.10 | 0.07 | 0.02 | 0.05 | 0.04 | 0.04 |
| EBITDA | 0.03 | 0.01 | (0.14) | (0.12) | 0.56 | (0.17) | (0.15) |
| EBITDA margin | +11.5% | +5.3% | -350.0% | -1200.0% | +5.9% | - | - |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.03 | 0.01 | (0.14) | (0.12) | 0.56 | (0.34) | (0.15) |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net profit | 0.03 | 0.01 | (0.14) | (0.12) | 0.56 | (0.34) | (0.15) |
| Net profit margin | +11.5% | +5.3% | -350.0% | -1200.0% | +5.9% | - | - |
| EPS (₹) | 0.00 | 0.00 | (0.02) | (0.02) | 0.08 | (0.05) | (0.02) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 6.61 | 6.61 | 6.61 | 6.61 | 6.61 | 6.61 | 6.61 |
| Reserves & surplus | (1.21) | (1.23) | (1.23) | (1.09) | (0.97) | (1.52) | (1.18) |
| Shareholders' funds (net worth) | 5.40 | 5.38 | 5.38 | 5.52 | 5.64 | 5.09 | 5.43 |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unsecured loans | 0.00 | 0.00 | 0.00 | 0.09 | 0.08 | 0.00 | 0.00 |
| Total debt | 0.00 | 0.00 | 0.00 | 0.09 | 0.08 | 0.00 | 0.00 |
| Total liabilities | 5.40 | 5.38 | 5.37 | 5.61 | 5.72 | 5.09 | 5.43 |
| Assets | |||||||
| Gross block | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net block | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 3.77 | 2.38 | 2.27 | 4.57 | 4.69 | 3.04 | 5.37 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sundry debtors | 0.00 | 0.00 | 0.00 | 0.00 | 6.22 | 0.00 | 0.00 |
| Cash & bank balances | 0.59 | 0.02 | 0.02 | 0.01 | 0.01 | 0.02 | 0.03 |
| Loans & advances | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total current assets | 0.61 | 0.02 | 0.02 | 0.01 | 6.23 | 0.02 | 0.03 |
| Total current liabilities | 2.03 | 3.08 | 0.02 | 0.04 | 6.27 | 0.54 | 0.60 |
| Net working capital | (1.42) | (3.06) | 0.00 | (0.03) | (0.04) | (0.52) | (0.57) |
| Total assets | 5.40 | 5.38 | 5.37 | 5.61 | 5.72 | 5.09 | 5.43 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.02 | 0.02 | 0.01 | 0.01 | 0.02 | 0.03 | 0.02 |
| Net cash from operating activities | (1.06) | 3.07 | (0.17) | (0.13) | 0.06 | (0.39) | 4.89 |
| Net cash from investing activities | 1.63 | (3.07) | 0.27 | 0.13 | (0.15) | 0.39 | (4.89) |
| Net cash from financing activities | 0.00 | 0.00 | (0.09) | 0.01 | 0.08 | 0.00 | 0.00 |
| Net change in cash | 0.57 | 0.00 | 0.01 | 0.00 | (0.01) | (0.01) | 0.01 |
| Closing cash | 0.59 | 0.02 | 0.02 | 0.01 | 0.01 | 0.02 | 0.03 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +36.8% | +375.0% | +300.0% | -99.9% | - | - | - |
| EBITDA growth | +200.0% | +107.1% | -16.7% | -121.4% | +429.4% | -13.3% | - |
| PBT growth | +200.0% | +9998.0% | -16.7% | - | +9998.0% | -126.7% | - |
| Net income growth | +200.0% | +107.1% | -16.7% | -121.4% | +264.7% | -126.7% | - |
| Revenue CAGR (3Y) | +196.3% | -72.9% | - | - | +101.0% | - | - |
| EBITDA CAGR (3Y) | - | -73.9% | -6.3% | -7.2% | +282.6% | +104.1% | -45.8% |
| Profitability & leverage | |||||||
| Net income margin | +11.5% | +5.3% | -350.0% | -1200.0% | +5.9% | - | - |
| Return on capital employed | - | +0.2% | 0.0% | 0.0% | +9.3% | 0.0% | 0.0% |
| Return on net worth | - | +0.2% | 0.0% | 0.0% | +9.3% | 0.0% | 0.0% |
| Debt / equity | - | 0.00 | 0.01 | 0.02 | 0.01 | 0.00 | 0.00 |
| Long-term debt / equity | - | 0.00 | 0.01 | 0.02 | 0.01 | 0.00 | 0.00 |
| Interest cover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory turnover | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debtors turnover | - | 0.00 | 0.00 | 0.00 | 3.08 | 0.00 | 0.00 |
| EPS (₹) | 0.00 | 0.00 | (0.02) | (0.02) | 0.08 | (0.05) | (0.02) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 0.81 | 0.81 | 0.84 | 0.85 | 0.77 | 0.82 |
To see the full year-wise statements and ratios of Amerise Biosciences Limited, buy the company report.
Board of directors of Amerise Biosciences Limited
Amerise Biosciences has 3 current directors and 21 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Manisha Patel Maneklal Also directs: Amraworld Agrico Limited, Presha Metallurgical Limited, Parichay Infrastructure Limited and 1 more | Director | 24 Jun 2019 | 7 Years 4 Months | Current |
| Albert Hines Also directs: Parichay Infrastructure Limited, Nilmesh Infrabuild LLP | Whole-Time Director | 02 Feb 2026 | 0 Years 9 Months | Current |
| Kelash Bunkar Also directs: Biogen Pharmachem Industries Limited, Regis Industries Limited | Director | 03 Feb 2025 | 1 Years 9 Months | Current |
Auditor
Amerise Biosciences Limited is audited by BIPIN & CO for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| BIPIN & CO | FY 2023 | 101509W |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 0.00%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 100.00%.
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 0.00% | 0.00% | 0.00% | 0.00% |
| Public | 100.00% | 100.00% | 100.00% | 100.00% |
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 17 Mar 1987 | 90097221 | Bank of Baroda | ₹9 Lakh | Open | |
| 20 Aug 1985 | 90097165 | Gujarat State Financial Corporation | ₹29.39 Lakh | Open |
To see the full charge records of Amerise Biosciences Limited, buy the company report.
Total charge records: 2 View all charges
Deals & funding
Amerise Biosciences Limited has 28 deals on record (28 market trades); the latest was in July 2026.
Deals on record (5 of 28)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Jul 2026 | Market trade | ₹4 Lakh | Seller: an individual |
| Apr 2026 | Market trade | ₹2.8 Lakh | Buyer: Snehjeev Ventures Private Limited Seller: an individual |
| Feb 2026 | Market trade | ₹3.9 Lakh | Buyer: an individual Seller: an individual |
| Oct 2025 | Market trade | ₹2.8 Lakh | Seller: an individual |
| Feb 2010 | Market trade | ₹13.46 Cr | Buyer: Parvati Minerals Private Limited Seller: Anukaran Commercial Enterprises Limited |
To see the full deal history of Amerise Biosciences Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
No court or tribunal cases involving Amerise Biosciences Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Amerise Biosciences Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
No GST registration is on our record for Amerise Biosciences Limited; the GSTIN and return-filing check is in the company report Buy the company report.
Recent activity
Amerise Biosciences Limited has 23 board changes on record since 2008: 3 appointments and 20 cessations. The latest: Albert Hines was appointed as Whole-Time Director on 02 Feb 2026.
18 earlier events are in the company report.
Frequently asked questions
Amerise Biosciences is an active public limited company based in Ahmedabad, Gujarat, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 27 August 1984 (42+ years old) and is registered under CIN L29199GJ1984PLC007195. Listed on BSE: 531681.
Amerise Biosciences reported revenue of ₹26 Lakh for FY 2025-26 (up 36.8% YoY) based on standalone financials.
Amerise Biosciences has 3 current directors:
- Albert Hines - Whole-Time Director
- Manisha Patel Maneklal - Director
- Kelash Bunkar - Director
The latest financial statements of Amerise Biosciences on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 23 September 2025. Year-wise statements from 2015 are in the company report.
The CIN (Corporate Identification Number) of Amerise Biosciences is L29199GJ1984PLC007195. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Amerise Biosciences is a listed company as per MCA records. Its shares are listed on BSE (code: 531681).
Amerise Biosciences was incorporated on 27 August 1984, making it 42+ years old. It is registered with the Registrar of Companies, Ahmedabad.
Amerise Biosciences has 28 deals on record (28 market trades); the latest was in July 2026.
Albert Hines was appointed as Whole-Time Director on 02 Feb 2026. Dineshkumar Tribhovanbhai Rathod ceased to be Whole-Time Director on 02 Feb 2026. Kelash Bunkar was appointed as Director on 03 Feb 2025. Amerise Biosciences has 23 board changes on record in total.
Amerise Biosciences can be reached through the website amradeepindustries.in. Its registered office is in Ahmedabad, Gujarat, India.

